☆ 4.2 Meeting Abstract

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Get Full Text
Add to Collection

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 19, Issue -, Pages S280-S281

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2019.07.217

Keywords

acalabrutinib; phase 3; BTK inhibitors; CD20; chronic lymphocytic leukemia; CLL

Categories

Oncology Hematology

Funding

  1. Acerta Pharma [NCT02970318]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.